Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease

Status Recruiting

Clinical Trial Summary

Justification: Studies in recent years have shown that suffering an episode of acute kidney injury (AKI) is an independent risk factor for developing chronic kidney disease (CKD), which is associated with cardiovascular complications, increases medical care costs, and decreases survival. These AKI to ERC transition cases add to the growing number of CKD cases already being seen globally. It is for them that in recent years therapeutic strategies have been sought to reduce or stop this process of transition from AKI to CKD. Objective: To evaluate the efficacy and safety of the use of dapagliflozin plus standard medical treatment (TMS), compared with only TMS for 21 days, in hospitalized patients with a diagnosis of severe AKI (KDIGO 3) in reducing the incidence of CKD to 18 months of follow-up. Design: Randomized, single center, open study. 100 hospitalized patients with a diagnosis of AKI KDIGO 3, without previous CKD, will be randomized to receive 10 mg of dapagliflozin every 24 h for 21 days + TMS or only TMS. During their follow-up, baseline blood and urine samples will be taken and at 3, 6, 12 and 18 months. At 18 months, the development of CKD will be assessed using the KDIGO clinical criteria and with the determination of urinary biomarkers (Serpina A3, HSP72, KIM 1 and NGAL).

Clinical Trial Description

It is planned to randomize 100 patients, 50 for each arm of the study. The randomization will be 1: 1 based on an open access computer program. Group 1: Dapagliflozin 10 mg, will be administered orally or by nasogastric tube every 24 h for 21 days. Group 2: Standard of care strategy, patients will receive the usual treatment for their pathology according to the judgment of their treating physician and the Institutional practices, without receiving any of the interventional drugs. Eligibility: Adults (aged >18 years) with AKI 3 diagnosis for less than 24 h (KDIGO classification, creatinine level or urine output criteria), hospitalized in general admission floor and/or intensive care unit. AKI diagnosis must be compatible with the diagnosis of acute tubular necrosis in a context of ischemic or toxic aggression. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05713851
Study type	Interventional
Source	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Contact
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	January 1, 2023
Completion date	January 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05095324` - The Biomarker Prediction Model of Septic Risk in Infected Patients
Recruiting	`NCT05548933` - Effects of Non-surgical Periodontal Therapy on Severe Periodontitis and Hyperlipidemia
Active, not recruiting	`NCT03926572` - Acute Decompensation of Pulmonary Hypertension	N/A
Recruiting	`NCT05372159` - Vanderbilt Memory and Aging Project
Completed	`NCT03173586` - Sugar Sweetened Beverage Intake and Biomarkers of Cardiometabolic Risk in US Women	N/A
Completed	`NCT04554628` - Early Prediction of Acute Kidney Injury Among Patients Admitted to Surgical ICU	N/A
Terminated	`NCT03250312` - The Effects of OMT on the Expression Patterns of Immune Cell Biomarkers	N/A
Recruiting	`NCT04666766` - Detecting Traumatic Intracranial Hemorrhage With Microwaves and Biomarkers	N/A
Completed	`NCT04573543` - The Role of Immune Semaphorins in NAFLD
Completed	`NCT03193671` - Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis	N/A
Recruiting	`NCT06047132` - PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED SUBJECTS
Completed	`NCT05361460` - Patients Experiences of Early Postoperative Cognition
Recruiting	`NCT05706194` - Early Neuroprognostication After OHCA
Recruiting	`NCT05138731` - Metabolomics Profiling of Coronary Heart Disease
Not yet recruiting	`NCT04563000` - Impact of Vitamin C on Biomarkers of Neurologic Injury in Survivors of Cardiac Arrest	Phase 2
Completed	`NCT05138692` - Biomarkers and Outcome 1 and 10-15 Years After Severe Traumatic Brain Injury
Completed	`NCT02247999` - Improving Cervical Cancer Screening Among HIV-Infected Women in India
Active, not recruiting	`NCT02732301` - Postoperative Gastrointestinal Dysfunction After Cardiac Surgery - Occurrence and Search for Biomarkers
Not yet recruiting	`NCT03269019` - Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia	N/A
Recruiting	`NCT04062279` - Predictors of Parkinson's Disease Progression

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study — DAKI-CKD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms